Get started
Author

Víctor Rodríguez-Freixinós

Observed names: V. Rodriguez-Freixinos, V. Rodríguez-Freixinos, V. Rodríguez-Freixinós, VICTOR RODRIGUEZ-FREIXINOS, Victor Rodriguez-Freixinos, Victor Rodríguez-Freixinos, Víctor Rodriguez-Freixinos, Víctor Rodríguez-Freixinos
Observed institutions: Universitat Autònoma de Barcelona, Sunnybrook Health Science Centre, University Health Network, University of Toronto, Princess Margaret Cancer Centre, Debiopharm (Switzerland), Vall d'Hebron Hospital Universitari, Sunnybrook Hospital, Vall d'Hebron Institute of Oncology, Odette Cancer Centre
OpenAlex ID: A5027395866
Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients
2013 · Pablo Martinez, Javier Hernández-Losa, et al. · PLoS ONE · 73
PDF
Exploratory analysis of activation of PTEN–PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)
2012 · S. Cedrés, M.A. Montero, et al. · Lung Cancer · 69
Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer
2019 · Isidre Felip, Cristian Pablo Moiola, et al. · Gynecologic Oncology · 43
Avelumab in unresectable/metastatic, progressive, grade 2–3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials
2022 · D.L. Chan, V. Rodriguez-Freixinos, et al. · European Journal of Cancer · 37
Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials.
2018 · Ignacio Matos, Juan Martin-Liberal, et al. · Journal of Clinical Oncology · 35
Biomarkers in colorectal cancer
2010 · Ben Markman, Víctor Rodríguez-Freixinos, et al. · Clinical & Translational Oncology · 32
A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors
2021 · Andres Poveda, Ana Oaknin, et al. · Scientific Reports · 18
PDF
Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era
2020 · Víctor Rodriguez-Freixinos, Jaume Capdevila, et al. · European Journal of Cancer · 16
PDF
Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients
2018 · V. Rodriguez-Freixinos, L. Fariñas-Madrid, et al. · Gynecologic Oncology · 16
New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?
2016 · Victor Rodriguez-Freixinos, Katherine Karakasis, et al. · Current Oncology Reports · 15
Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer
2019 · Victor Rodriguez-Freixinos, Fiorella Ruiz-Pace, et al. · ESMO Open · 14
PDF
A phase II study of pazopanib in recurrent or persistent ovarian (EOC), peritoneal (PPC), or Fallopian tube cancer (FTC): A Spanish Ovarian Cancer Group (GEICO) study.
2012 · Ana Oaknin, Antonio Gonzalez-Martin, et al. · Journal of Clinical Oncology · 13
Breaking down the evidence for bevacizumab in advanced cervical cancer: past, present and future
2015 · Victor Rodriguez-Freixinos, Helen J. Mackay · Gynecologic Oncology Research and Practice · 12
PDF
Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients
2019 · V. Rodriguez-Freixinos, S. Lheureux, et al. · Gynecologic Oncology · 11
Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study
2022 · Andres Poveda, Raquel Lopez-Reig, et al. · Cancers · 10
SEOM guidelines for cervical cancer
2012 · Ana Oaknin, Isabela Díaz de Corcuera, et al. · Clinical & Translational Oncology · 10
Current and emerging treatment options in the management of advanced ovarian cancer
2016 · Victor Rodriguez-Freixinos, Helen J. Mackay, et al. · Expert Opinion on Pharmacotherapy · 9
SEOM guidelines for endometrial cancer
2012 · Ana Oaknin, Víctor Rodríguez-Freixinós, et al. · Clinical & Translational Oncology · 9
A pilot study of everolimus and radiation for neuroendocrine liver metastases
2021 · Sten Myrehaug, David L Chan, et al. · Endocrine Related Cancer · 8
A randomized, placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum-resistant epithelial ovarian, primary peritoneal, or Fallopian tube cancers: Trial of Princess Margaret, Mayo, Chicago, and California consortia.
2015 · Stephanie Lheureux, Johanne Ingrid Weberpals, et al. · Journal of Clinical Oncology · 5
ALK rearrangement in a selected population of advanced non-small cell lung cancer patients: FISH and inmunohistochemistry diagnostic methods, prevalence, and clinical outcomes.
2011 · P. Martinez, J. Hernandez-Losa, et al. · Journal of Clinical Oncology · 5
Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?
2021 · Victor Rodriguez-Freixinos, Alia Thawer, et al. · Current Oncology Reports · 4
Bevacizumab in the Treatment of Cervical Cancer – Current Evidence and Next Steps
2016 · Ana Oaknin, Victor Rodriguez-Freixinos · European Oncology & Haematology · 4
An analysis of malignant bowel obstruction (MBO) outcomes in patients with epithelial ovarian carcinoma (EOC).
2015 · Cristina Martin Lorente, Helen Mackay, et al. · Journal of Clinical Oncology · 3
Phase I study to evaluate the tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) of PM01183 (Lurbinectedin) in combination with olaparib in patients with advanced solid tumors.
2017 · Andres Poveda, Ana Oaknin, et al. · Journal of Clinical Oncology · 2
Works count: 44
Citation count: 478
H-index: 12
I10-index: 16
Year
Topic
Type